<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Neurology</journal-id>
<journal-id journal-id-type="iso-abbrev">Neurology</journal-id>
<journal-id journal-id-type="hwp">neurology</journal-id>
<journal-id journal-id-type="publisher-id">neur</journal-id>
<journal-id journal-id-type="pmc">neurology</journal-id>
<journal-id journal-id-type="publisher-id">NEUROLOGY</journal-id>
<journal-title-group>
<journal-title>Neurology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0028-3878</issn>
<issn pub-type="epub">1526-632X</issn>
<publisher>
<publisher-name>Lippincott Williams &amp; Wilkins</publisher-name>
<publisher-loc>Hagerstown, MD</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28251916</article-id>
<article-id pub-id-type="pmc">5373778</article-id>
<article-id pub-id-type="publisher-id">NEUROLOGY2016768655</article-id>
<article-id pub-id-type="doi">10.1212/WNL.0000000000003772</article-id>
<article-categories>
<subj-group subj-group-type="hwp-journal-coll">
<subject>283</subject>
<subject>285</subject>
<subject>91</subject>
<subject>181</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Genetic heterogeneity of motor neuropathies</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Bansagi</surname>
<given-names>Boglarka</given-names>
</name>
<degrees>MD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>(1) MRC Centre for Neuromuscular Diseases</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Griffin</surname>
<given-names>Helen</given-names>
</name>
<degrees>PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Whittaker</surname>
<given-names>Roger G.</given-names>
</name>
<degrees>MD, PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>Engineering and Physical Sciences Research Council EP/K028421/1 PI, 3 years</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Antoniadi</surname>
<given-names>Thalia</given-names>
</name>
<degrees>PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Evangelista</surname>
<given-names>Teresinha</given-names>
</name>
<degrees>MD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Miller</surname>
<given-names>James</given-names>
</name>
<degrees>MD, PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>I have served on scientific advisory boards for CSL Bering.</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for travel or speaker honoraria:</title>
<list-item>
<p>CSL Bering funded travel and accommodation to attend Peripheral Nerve Society meeting in 2015.</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Greenslade</surname>
<given-names>Mark</given-names>
</name>
<degrees>PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Forester</surname>
<given-names>Natalie</given-names>
</name>
<degrees>PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Duff</surname>
<given-names>Jennifer</given-names>
</name>
<degrees>PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bradshaw</surname>
<given-names>Anna</given-names>
</name>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kleinle</surname>
<given-names>Stephanie</given-names>
</name>
<degrees>PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Boczonadi</surname>
<given-names>Veronika</given-names>
</name>
<degrees>PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Steele</surname>
<given-names>Hannah</given-names>
</name>
<degrees>MD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ramesh</surname>
<given-names>Venkateswaran</given-names>
</name>
<degrees>MD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Franko</surname>
<given-names>Edit</given-names>
</name>
<degrees>MD, PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pyle</surname>
<given-names>Angela</given-names>
</name>
<degrees>PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lochmüller</surname>
<given-names>Hanns</given-names>
</name>
<degrees>MD, PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>(1) German Duchenne parents project (2)IRDiRC Interdisciplinary Scientific Committee (3)German Muscular Dystrophy Network (4) Myotubular Trust Patient Registry (5) Action Duchenne Patient Registry (6) German Patient Registries on DMD and SMA</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>(1)PTC Therapeutics Inc, honorarium for lecture at satellite symposium ICNMD Nice 2014 and travel paid to Newcastle University (2)Ultragenyx Pharmaceutical Inc., travel</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>(1) Journal of Neuromuscular Diseases, Editor in Chief, 2014- current (2)Journal of Neurology, Editorial Board Member, 2007- current</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>(1)Roche Pharmaceuticals (paid to Newcastle University) (2)ASD Therapeutics Partners LLC (paid to Newcastle University) (3)IOS Press (paid to Newcastle University) (4)Alexion Pharmaceuticals Inc.(paid to Newcastle University) (5)Ultragenyx Pharmaceutical Inc.(paid to Newcastle University) (6) Fondazione Cariplo (paid to Newcastle University)</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>(1) Marigold Foundation Ltd (2)Ultragenyx Pharmaceutical Inc (3)PTC Therapeutics Inc (4)Eli Lilly and co (5)Action Benni &amp; Co e.v (6)GSK (GlaxoSmithKline) (7)Trophos SA</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>(1)European Commission (RD-Connect), 305444, Coordinator, 2012-2018 (2) European Commission (OPTIMISTIC), 305697, co- investigator, 2012-2016 (3)European Commission (NeurOmics), 305121, co-investigator, 2012-2017 (4)Medical Research Council (MRC) G1002274, 98482, co-investigator, 2015-2016 (5)Medical Research Council (MRC), co-investigator, 2013- 2018 (6)National Institute for Health Research (NIHR)PD00402, 2015-2017</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>(1)Action Duchenne, (2) Association Francaise Contre les Myopathies (3)British Heart Foundation (4)Muscular Dytrophy UK (5)National Cancer Institute (6) Spinal Muscular Atrophy Support UK (7)Wellcome Trust (8)Jennifer Trust (9)Duchenne Parent Project</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chinnery</surname>
<given-names>Patrick F.</given-names>
</name>
<degrees>MD, FRCP, FMedSci</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>BRAIN, Associate Editor 2004</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>Medical Research Council (UK) NIHR (England)</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>Wellcome Trust</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Horvath</surname>
<given-names>Rita</given-names>
</name>
<degrees>MD, PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<aff>From the MRC Centre for Neuromuscular Diseases and John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine (B.B., H.G., T.E., J.D., A.B., V.B., H.S., E.F., A.P., H.L., P.F.C., R.H.), and Institute of Neuroscience (R.G.W., J.M.), Newcastle University, Newcastle upon Tyne; Bristol Genetics Laboratory (T.A., M.G., N.F.), Pathology Sciences, North Bristol NHS Trust, Southmead Hospital; Medical Genetic Center (S.K.), Munich, Germany; Department of Paediatric Neurology (V.R.), Royal Victoria Infirmary, Newcastle upon Tyne Foundation Hospitals NHS Trust; Nuffield Department of Clinical Neurosciences (E.F.), University of Oxford; and Department of Clinical Neurosciences (P.F.C.), Cambridge Biomedical Campus, University of Cambridge, UK.</aff>
</contrib-group>
<author-notes>
<corresp>Correspondence to Dr. Horvath: <email>Rita.Horvath@ncl.ac.uk</email></corresp>
<fn fn-type="financial-disclosure">
<p>Go to <ext-link ext-link-type="uri" xlink:href="http://neurology.org/lookup/doi/10.1212/WNL.0000000000003772">Neurology.org</ext-link> for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article. The Article Processing Charge was paid by Medical Research Council/Wellcome Trust.</p>
</fn>
</author-notes>
<pub-date pub-type="ppub">
<day>28</day>
<month>3</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>28</day>
<month>3</month>
<year>2017</year>
</pub-date>
<!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="ppub"/>. -->
<volume>88</volume>
<issue>13</issue>
<fpage>1226</fpage>
<lpage>1234</lpage>
<history>
<date date-type="received">
<day>05</day>
<month>9</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>06</day>
<month>1</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology</copyright-statement>
<copyright-year>2017</copyright-year>
<copyright-holder>American Academy of Neurology</copyright-holder>
<license license-type="open-access">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License 4.0 (CC BY)</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
</license>
</permissions>
<self-uri xlink:href="NEUROLOGY2016768655.pdf" xlink:title="pdf"></self-uri>
<abstract>
<sec>
<title>Objective:</title>
<p>To study the prevalence, molecular cause, and clinical presentation of hereditary motor neuropathies in a large cohort of patients from the North of England.</p>
</sec>
<sec>
<title>Methods:</title>
<p>Detailed neurologic and electrophysiologic assessments and next-generation panel testing or whole exome sequencing were performed in 105 patients with clinical symptoms of distal hereditary motor neuropathy (dHMN, 64 patients), axonal motor neuropathy (motor Charcot-Marie-Tooth disease [CMT2], 16 patients), or complex neurologic disease predominantly affecting the motor nerves (hereditary motor neuropathy plus, 25 patients).</p>
</sec>
<sec>
<title>Results:</title>
<p>The prevalence of dHMN is 2.14 affected individuals per 100,000 inhabitants (95% confidence interval 1.62–2.66) in the North of England. Causative mutations were identified in 26 out of 73 index patients (35.6%). The diagnostic rate in the dHMN subgroup was 32.5%, which is higher than previously reported (20%). We detected a significant defect of neuromuscular transmission in 7 cases and identified potentially causative mutations in 4 patients with multifocal demyelinating motor neuropathy.</p>
</sec>
<sec>
<title>Conclusions:</title>
<p>Many of the genes were shared between dHMN and motor CMT2, indicating identical disease mechanisms; therefore, we suggest changing the classification and including dHMN also as a subcategory of Charcot-Marie-Tooth disease. Abnormal neuromuscular transmission in some genetic forms provides a treatable target to develop therapies.</p>
</sec>
</abstract>
<funding-group>
<award-group>
<funding-source>Wellcome Trust</funding-source>
<award-id>(109915/Z/15/Z), (201064/Z/16/Z)</award-id>
</award-group>
<award-group>
<funding-source>Medical Research Council</funding-source>
<award-id>(MR/N025431/1)</award-id>
</award-group>
<award-group>
<funding-source>European Research Council</funding-source>
<award-id>(309548)</award-id>
</award-group>
<award-group>
<funding-source>NIH</funding-source>
</award-group>
</funding-group>
<custom-meta-group>
<custom-meta>
<meta-name>OPEN-ACCESS</meta-name>
<meta-value>TRUE</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body><p>Distal hereditary motor neuropathies (dHMN) are clinically and genetically heterogeneous disorders caused by lower motor neuron dysfunction.<sup><xref ref-type="bibr" rid="R1">1</xref></sup> The classic phenotype of dHMN is a length-dependent motor weakness and atrophy, initially affecting the intrinsic foot muscles and the peroneal compartment of the leg, frequently leading to foot deformities such as pes cavus, pes planus, and clawing of the toes.<sup><xref ref-type="bibr" rid="R2">2</xref></sup> The majority of the cases show a slowly progressive disease course gradually involving proximal leg muscles or affecting intrinsic hand muscles. Variable age at onset, diverse clinical course, and associated neurologic features complicate the phenotype and aid the clinical subclassification. Congenital or infantile-onset forms of weakness and atrophy of the feet and legs with no or very slow disease progression were grouped as spinal muscular atrophy with lower extremity dominance (SMA-LED). Other clinical subgroups of dHMN were classified on the basis of additional features such as diaphragmatic paralysis (dHMN-IV), upper limb predominance (dHMN-V), SMA with respiratory distress (SMARD1 or dHMN-VI), adult-onset with vocal cord palsy (dHMN-VII), and pyramidal features or X-linked inheritance.<sup><xref ref-type="bibr" rid="R3">3</xref></sup></p><p>Gene identification in dHMN was previously based on linkage studies in rare extended families. However, recent development of next-generation technology enabled studying isolated patients or small families, and a large number of new disease genes and novel phenotypes have been discovered.<sup><xref ref-type="bibr" rid="R4">4</xref></sup> Compared to the 7 genes and 13 chromosomal loci 10 years ago,<sup><xref ref-type="bibr" rid="R5">5</xref>,<xref ref-type="bibr" rid="R6">6</xref></sup> to date we acknowledge around 30 genes responsible for autosomal dominant, recessive, and X-linked forms of dHMN. To identify the molecular cause of motor neuropathies, we performed detailed clinical investigations and state of the art genetic studies in a large, population-based cohort from the North of England.</p><sec id="s1" sec-type="methods"><title>METHODS</title><sec id="s1-1"><title>Patients.</title><p>Between 2010 and 2015, we selected 105 patients out of 461 diagnosed with inherited neuropathies in our genetic neuropathy clinic at Newcastle Hospitals NHS Foundation, which is the catchment area of a total population of 2.99 million. Inclusion of patients was based on the presence of a motor neuropathy/neuronopathy with no or only subclinical sensory changes on electrophysiology. Acquired causes were excluded by detailed laboratory analysis/no response on immunosuppressive therapy. Some affected family members of patients with a confirmed genetic diagnosis were included in this cohort, even if no electrophysiologic data were available.</p></sec><sec id="s1-2"><title>Standard protocol approvals, registrations, and patient consents.</title><p>Participants provided written informed consent, approved by local research ethics committees, for all experiments using human participants and for photographs that may be published.</p></sec><sec id="s1-3"><title>Electrophysiology.</title><p>We performed electrophysiologic examination in 90 patients according to standard techniques and interpreted by the same expert neurophysiologists. Eight family members did not undergo electrophysiologic studies; 7 patients were tested at different hospitals. Motor and sensory nerve conduction studies (NCS) were performed and qualitative and quantitative analysis of motor unit potentials and spontaneous activity were assessed on EMG. Patient classification into study groups was based on these analyses. Additional assessment of repetitive nerve stimulation and single-fiber EMG were carried out in 27 patients, and the percentage increment or decrement was calculated. EMG was performed using Natus Neurology (Pleasanton, CA) disposable 30-G concentric needles with a bandpass range of 10–10,000 Hz. For single-fiber EMG studies, the low pass filter was increased to 2,000 Hz and the percentage of fiber pairs showing increased jitter or blocking was calculated.</p></sec><sec id="s1-4"><title>Molecular genetic analysis.</title><p>DNA was obtained from peripheral blood. Initially, <italic>PMP22</italic> deletion/duplication, <italic>MFN2</italic>, and <italic>GJB1</italic> were excluded in all patients. The multigene panel assay utilizing next-generation sequencing (NGS) was carried out in 46 index patients in the Bristol Genetics Laboratory following the UK Genetic Testing Network approved criteria. Variant classification was based on Association for Clinical Genetic Science Practice Guidelines (2013). We performed whole exome sequencing (WES) in 40 patients. DNA was fragmented, exome-enriched, and sequenced (Illumina [San Diego, CA] TruSeq 62 Mb and HiSeq 2000, 100 bp paired-end reads). Bioinformatic analysis included duplicate sequence read removal with FastUniq,<sup><xref ref-type="bibr" rid="R7">7</xref></sup> alignment to UCSC hg19 with BWA<sup><xref ref-type="bibr" rid="R8">8</xref></sup> variant detection with FreeBayes, and variant annotation with ANNOVAR. Variants were annotated as exonic/splicing, excluding synonymous variants, with a rare minor allele frequency (MAF &lt; 0.01) in the context of genotype (heterozygous MAF &lt; 0.001; homozygous MAF &lt; 0.01) in several databases downloaded via ANNOVAR (ExAC, NHLBI_ESP6500, cg69) and also in 281 in-house exomes. Protein prediction and evolutionary sequence conservation algorithms downloaded via ANNOVAR were used to analyze the in silico effects following the guidelines of the American College of Medical Genetics and Genomics.<sup><xref ref-type="bibr" rid="R9">9</xref></sup> Variants were defined as confirmed pathogenic if they were previously shown to be pathogenic or if they were novel variants in a known neuropathy-associated gene, predicted to be deleterious (affect protein structure or function, highly conserved), and segregated with the disease in at least 1 additional affected family member.<sup><xref ref-type="bibr" rid="R10">10</xref></sup> Highly conserved, in silico deleterious rare sequence variants of known or novel genes were determined as possible pathogenic if segregation studies involving at least one additional affected family member could not be carried out. Putative pathogenic variants were confirmed by Sanger sequencing and were tested for segregation.</p></sec></sec><sec id="s2" sec-type="results"><title>RESULTS</title><sec id="s2-1"><title>Clinical presentation.</title><p>We identified 105 patients from 73 families with inherited motor neuropathies. Based on neurologic and electrophysiologic findings, all patients were classified into 1 of 3 subgroups: dHMN, motor predominant Charcot-Marie-Tooth disease (CMT2) (motor CMT2), and motor neuropathy with additional neurologic symptoms (hereditary motor neuropathy [HMN] plus). Diagnosis of dHMN was based on preserved sensory nerve studies with normal or reduced compound motor unit action potentials or neurogenic changes on EMG examination.<sup><xref ref-type="bibr" rid="R2">2</xref></sup> Patients with dHMN but with decreased sensory nerve action potentials, indicative of an accompanying sensory axonopathy, were grouped as motor CMT2. We considered HMN plus when motor neuropathy was the leading feature, but was accompanied by other neurologic symptoms. NCS data of all patients are available on request.</p><p>All patients seen in our center were from our catchment area (2.99 million people in 2011 UK census), leading to a minimum prevalence of dHMN as 2.14 affected individuals per 100,000 inhabitants (95% confidence interval [CI] 1.62–2.66).</p><p>Sixty-four out of 105 patients (60.9%) had dHMN. Sixteen patients had motor CMT2 (15.2%) and 25 HMN plus (23.8%) (<xref ref-type="fig" rid="F1 F2 F3">figures 1–3</xref>). There was male predominance in all phenotypic groups. Symptoms started at a younger age in dHMN (mean 16 years) and HMN plus (mean 17.6 years) compared to motor CMT2 (mean 23.8 years). The main inheritance pattern was autosomal dominant in CMT2 (7/10 families [70%]) while isolated cases were more frequent in HMN plus. The dHMN group consisted of an almost equal number of dominant families (n = 16) and isolated patients with negative or unavailable family history (n = 20).</p><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><title>Clinical heterogeneity of different forms of hereditary motor neuropathy (HMN)</title><p>Distal hereditary motor neuropathy (dHMN) (top 2 rows), motor Charcot-Marie-Tooth disease 2 (CMT2) (third row), and HMN plus (bottom row): (A) patients 2 and 3: <italic>GARS</italic>; (B) patient 19: <italic>IGHMBP2</italic>; (C) patient 23: <italic>TRPV4</italic>; (D) patient 32: <italic>IGHMBP2</italic>; (E) not yet diagnosed dHMN; (F) patient 18: <italic>DYNC1H1</italic>; (G) patient 10: <italic>SYT2</italic>; (H) patient 16: <italic>BICD2</italic>; (I, J) not yet diagnosed spinal muscular atrophy lower extremity dominance; (K) patient 42: <italic>AARS</italic>; (L) patient 39: <italic>AARS</italic>; (M) family 22: <italic>DNM2</italic>; (N) patient 51: <italic>FUS</italic>; (O) patient 53: <italic>ATP7A</italic>; (P) patient 57: <italic>TBX5</italic>; (Q) patient 58: <italic>STAT5B</italic>; (R) not yet diagnosed HMN plus.</p></caption><graphic xlink:href="NEUROLOGY2016768655FF1"></graphic></fig><fig id="F2" orientation="portrait" position="float"><label>Figure 2</label><caption><title>Identified genes in our hereditary motor neuropathy (HMN) patient cohort</title><p>(A) Spectrum and distribution of mutated genes detected in our cohort within the 3 phenotypic groups. (B) Overlapping clinical phenotypes related to the identified genes and key additional clinical features associated. *Upper motor neuron involvement. ALS = amyotrophic lateral sclerosis.</p></caption><graphic xlink:href="NEUROLOGY2016768655FF2"></graphic></fig><fig id="F3" orientation="portrait" position="float"><label>Figure 3</label><caption><title>Diagnostic flow chart and mutation detection rates in our hereditary motor neuropathy (HMN) cohort</title><p>CMT = Charcot-Marie-Tooth disease; dHMN = distal hereditary motor neuropathy; WES = whole exome sequencing.</p></caption><graphic xlink:href="NEUROLOGY2016768655FF3"></graphic></fig><p>We identified causative mutations in 26 out of 73 families, providing a 35.6% mutation detection rate (<xref ref-type="fig" rid="F2">figure 2</xref>). Candidate gene sequencing based on clinical presentation led to the molecular diagnosis in 5 out of 105 patients only (4.7%), while 12 index patients were diagnosed by NGS panel from 46 performed tests (26%) and a further 18 index patients by WES (total 40 analysis) (45%). There were no novel shared genes/mutations in the exome negative cases.</p></sec><sec id="s2-2"><title>Mutation spectrum in dHMN.</title><p>We achieved the possible genetic diagnosis in 17/40 families, which resulted in 42.5% detection rate (<xref ref-type="fig" rid="F2">figure 2</xref>). Variants were considered confirmed pathogenic in 13 index cases (32.5%); 7 of them carried known pathogenic dHMN mutations while in 6 families novel deleterious variants were detected in known genes and segregated with the phenotype (table e-1A at <ext-link ext-link-type="uri" xlink:href="http://neurology.org/lookup/doi/10.1212/WNL.0000000000003772">Neurology.org</ext-link>).</p><p>A previously reported heterozygous c.421A&gt;G, p.(Lys141Glu) mutation in <italic>HSPB8</italic> presented with a progressive lower limb predominant phenotype (family 1). We found 2 novel <italic>GARS</italic> mutations in 2 independent families (families 2–3). The heterozygous c.647A&gt;G, p.(His216Arg) was detected in a mother and her son with predominant upper extremity involvement (dHMN-V) (<xref ref-type="fig" rid="F1">figure 1A</xref>). The c.1528A&gt;C, p.(Lys510Gln) mutation cosegregated in 3 generations with dominant distal motor neuropathy affecting both upper and lower extremities. Electrophysiologic examination revealed mildly increased jitter in one patient consistent with a motor neuropathy and significantly increased jitter with blocking in another patient. One patient with dHMN involving both upper and lower limbs carried the previously reported c.1834G&gt;A, p.(Val612Met) mutation in <italic>DYNC1H1</italic> (family 7) (<xref ref-type="fig" rid="F1">figure 1F</xref>). A rapidly progressive dHMN in a 15-year-old boy was due to the de novo previously reported c.1126A&gt;G, p.(Met376Val) mutation in <italic>MFN2</italic> (family 12).<sup><xref ref-type="bibr" rid="R11">11</xref></sup> The heterozygous c.2119C&gt;T p.(Arg707Trp) <italic>MFN2</italic> mutation was found in a 70- year-old man with late-onset dHMN (family 13).<sup><xref ref-type="bibr" rid="R12">12</xref></sup></p><p>The homozygous frameshift c.292_303delinsATGCT p.(Gly98fs) mutation in <italic>IGHMBP2</italic> led to SMARD1 in 2 siblings of consanguineous Pakistani origin (family 8) (<xref ref-type="fig" rid="F1">figure 1B</xref>). A brother and sister from another family with childhood-onset distal SMA and lack of respiratory involvement carried a heterozygous c.1813C&gt;T p.(Arg605*) nonsense <italic>IGHMBP2</italic> mutation, which was hemizygous in the cDNA (family 9).<sup><xref ref-type="bibr" rid="R13">13</xref></sup></p><p>We have previously reported 6 patients with nonprogressive neuropathy and fatigable weakness carrying c.923C&gt;T; p.(Pro308Leu) in <italic>SYT2</italic> (family 4) (<xref ref-type="fig" rid="F1">figure 1G</xref>),<sup><xref ref-type="bibr" rid="R14">14</xref></sup> 5 patients with distal congenital nonprogessive SMA carrying c.320C&gt;T, p.(Ser107Leu) in <italic>BICD2</italic> (families 5–6) (<xref ref-type="fig" rid="F1">figure 1H</xref>),<sup><xref ref-type="bibr" rid="R15">15</xref></sup> and 2 patients with <italic>TRPV4</italic> mutations associated with childhood-onset scapuloperoneal SMA and metatropic dysplasia (family 10) (<xref ref-type="fig" rid="F1">figure 1C</xref>) or adult-onset dHMN (family 11).<sup><xref ref-type="bibr" rid="R16">16</xref></sup></p><p>Possibly causative mutations were detected in 4 families (table e-1B). The heterozygous novel c.2752C &gt; T, p.(Arg918Cys) <italic>IGHMBP2</italic> variant was detected in 3 siblings with motor neuropathy, without respiratory dysfunction (family 14). All prediction tools predicted this change pathogenic, and it was absent in the ExAC database, although we could not identify a second mutation in this family. The single heterozygous c.767C&gt;G, p.(Ala256Gly) <italic>IGHMBP2</italic> variant was detected in a 3.5-year-old boy with compatible phenotype (family 15) (<xref ref-type="fig" rid="F1">figure 1D</xref>). In 3 members of a dominant dHMN pedigree (family 16), we found a novel heterozygous <italic>DHTKD1</italic> variant c.628G&gt;T, p.(Ala210Ser). In a young female patient (family 17) we identified a heterozygous novel c.1949G&gt;A, p.(Tyr650Cys) sequence change in <italic>ARHGEF10</italic>.</p></sec><sec id="s2-3"><title>Mutation spectrum in motor CMT2.</title><p>Motor CMT2 was considered in 16 patients from 10 families. We achieved 70% mutation detection rate in this group by concluding molecular diagnosis in 7 CMT2 families (<xref ref-type="fig" rid="F2">figure 2</xref>) (table e-2). We identified the recurrent c.986G&gt;A, p.(Arg329His) <italic>AARS</italic> mutation in 6 patients from 4 families (families 18–21) (<xref ref-type="fig" rid="F1">figure 1, K and L</xref>).<sup><xref ref-type="bibr" rid="R17">17</xref></sup> In 3 members of a dominant family with early-onset intermediate motor neuropathy, split hand deformity, and hearing loss, we detected the previously described c.1739T&gt;C, p.(Met580Thr) <italic>DNM2</italic> mutation (family 22) (<xref ref-type="fig" rid="F1">figure 1M</xref>).<sup><xref ref-type="bibr" rid="R18">18</xref></sup> A female patient with upper limb weakness carried the pathogenic c.1403G&gt;A, p.(Arg468His) <italic>MFN2</italic> mutation (family 23).<sup><xref ref-type="bibr" rid="R12">12</xref></sup> Exome sequencing of male monozygotic twins with early-onset severe motor predominant neuropathy revealed the recently reported heterozygous c.754C&gt;T, p.(Arg252Trp) mutation in the <italic>MORC2</italic> gene (family 24).<sup><xref ref-type="bibr" rid="R19">19</xref></sup></p></sec><sec id="s2-4"><title>Mutation spectrum in HMN plus families.</title><p>Twenty-five patients from 23 families with predominant motor neuropathy had additional neurologic features. Confirmed pathogenic mutations were detected in 6 patients (26%) and a probable disease cause was identified in a further 5 index patients (21.7%) (<xref ref-type="fig" rid="F2">figure 2</xref>, table e-3A). The heterozygous c.1529A&gt;G p.(Lys510Arg) <italic>FUS</italic> mutation was detected in a 52-year-old man with asymmetric lower limb motor neuropathy. The progression was rapid with evolving motor neuron disease, frontal dementia, and loss of ambulation within half a year (family 27) (<xref ref-type="fig" rid="F1">figure 1N</xref>). WES identified a hemizygous c.2279A&gt;G, p.(Tyr760Cys) novel <italic>ATP7A</italic> variant with upper and lower motor neuron symptoms (family 29) (<xref ref-type="fig" rid="F1">figure 1O</xref>).<sup><xref ref-type="bibr" rid="R20">20</xref></sup> We detected compound heterozygous c.916G&gt;A, p.(Gly306Arg) and c.1016T&gt;C, p.(Leu339Pro) mutations in <italic>SLC52A2</italic> (family 25)<sup><xref ref-type="bibr" rid="R21">21</xref></sup> and a homozygous c.96_99dupATCC, p.(Pro34Ilefs*25) mutation in the <italic>c12orf65</italic> gene (family 26).<sup><xref ref-type="bibr" rid="R22">22</xref></sup> Distal motor neuropathy with ataxia and dystonia was associated with c.3823C&gt;T p.(Arg1275Cys) in <italic>DCTN1</italic> (family 28).<sup><xref ref-type="bibr" rid="R23">23</xref></sup> Compound heterozygous c.1580C&gt;G, p.(Ser527*) and c.6781C&gt;A, p.(Leu2261Ile) mutations in <italic>SACS</italic> caused juvenile-onset motor neuropathy, ataxia, and spasticity in a 71-year-old man (family 30).<sup><xref ref-type="bibr" rid="R24">24</xref></sup> Possibly causative mutations were detected in 5 families (table e-3B). A 17-year-old man with distal motor neuropathy and optic atrophy (CMT type 6) carried a single previously reported heterozygous c.2386C&gt;T, p.(Gln796*) mutation in <italic>FIG4</italic>.<sup><xref ref-type="bibr" rid="R25">25</xref></sup> Heterozygous <italic>FIG4</italic> mutations have been associated with adult-onset amyotrophic lateral sclerosis but without optic atrophy.<sup><xref ref-type="bibr" rid="R26">26</xref></sup> We found the heterozygous c.1371C&gt;G, p.(Phe457Leu) mutation in <italic>SLC52A3</italic> in a 19-year-old man with Brown-Vialetto-Van-Laere syndrome, who responded well to riboflavin therapy. However, we could not identify a second mutation, even by analyzing WES for copy number variations within this gene (family 32). A 19-year-old man with shoulder girdle weakness commonly seen in Holt-Oram syndrome carried the previously reported c.331G&gt;T, p.(Asp111Tyr) <italic>TBX5</italic> mutation (family 33, <xref ref-type="fig" rid="F1">figure 1P</xref>).<sup><xref ref-type="bibr" rid="R27">27</xref></sup> We identified the novel homozygous c.944T&gt;G, p.(Glu315Ala) mutation in the transcriptional factor <italic>STAT5B</italic> in a sibling pair from a consanguineous family with growth retardation, dysmorphic face, and motor neuropathy (family 34) (<xref ref-type="fig" rid="F1">figure 1Q</xref>). Asymmetric motor neuron weakness, cranial nerve involvement, pyramidal signs, and multifocal motor neuropathy with conduction blocks were observed in a man who carried a novel de novo c.269T&gt;C, p.(Phe90Ser) mutation in <italic>PTEN</italic> (family 35).</p></sec></sec><sec id="s3" sec-type="discussion"><title>DISCUSSION</title><p>Although HMNs are suggested to be rare, we identified 105 patients in the North of England, with a population of 2.99 million. We previously determined that the minimum prevalence of CMT in the North of England is 11.8 per 100,000 individuals.<sup><xref ref-type="bibr" rid="R28">28</xref>,<xref ref-type="bibr" rid="R29">29</xref></sup> Here we report that the minimum prevalence of dHMN in the same population is 2.14 affected individuals per 100,000 inhabitants (95% CI 1.62–2.66), which is higher than suggested earlier.<sup><xref ref-type="bibr" rid="R29">29</xref>,<xref ref-type="bibr" rid="R30">30</xref></sup></p><p>Previous studies indicated that the molecular cause can be identified in the vast majority of patients with demyelinating CMT; however, the detection rate has been much lower in dHMN and motor CMT2 (∼20).<sup><xref ref-type="bibr" rid="R3">3</xref></sup> We identified potentially pathogenic mutations in 47.9% (35/73 families), which consisted of confirmed mutations in 35.6% and possibly causative variants in an additional 12.3%. Previously in dHMN, the detection rate was 15%–20%.<sup><xref ref-type="bibr" rid="R3">3</xref>,<xref ref-type="bibr" rid="R5">5</xref>,<xref ref-type="bibr" rid="R6">6</xref>,<xref ref-type="bibr" rid="R31">31</xref></sup> We confirmed genetic diagnosis in 32.5% (13/40 families) of dHMN, and a likely causative mutation was identified in an additional 10% (<xref ref-type="fig" rid="F2">figure 2</xref>), which is higher than in previous studies (tables e-4–e-6).</p><p>dHMN is strictly considered as the pure motor end of CMT, many patients show minor sensory abnormalities,<sup><xref ref-type="bibr" rid="R1">1</xref>,<xref ref-type="bibr" rid="R6">6</xref></sup> and mutations in the same gene can cause both dHMN and CMT2.<sup><xref ref-type="bibr" rid="R2">2</xref>,<xref ref-type="bibr" rid="R31">31</xref></sup> HMN may be complicated by SMA, spastic paraplegia, or other neurologic abnormalities.<sup><xref ref-type="bibr" rid="R1">1</xref>,<xref ref-type="bibr" rid="R6">6</xref>,<xref ref-type="bibr" rid="R32">32</xref></sup> Affected pathways linked to dHMN include DNA/RNA metabolism, protein translation and synthesis, stress response, apoptosis, axonal guidance, intracellular trafficking, and synaptic activity (<xref ref-type="fig" rid="F4">figure 4</xref>). Mitochondrial abnormalities are common in our cohort in all forms of motor neuropathies and contribute to the symptoms by altering mitochondrial fusion/fission (<italic>MFN2, DNM2, SLC25A46</italic>), axonal transport (<italic>HSPB1, HSPB8</italic>), protein synthesis (<italic>C12orf65, SACS</italic>), or cofactors (<italic>SLC52A2/3</italic>).</p><fig id="F4" orientation="portrait" position="float"><label>Figure 4</label><caption><title>Pathomechanisms of genes reported in hereditary motor neuropathy (HMN)</title></caption><graphic xlink:href="NEUROLOGY2016768655FF4"></graphic></fig><p>SMA-LED has been introduced to characterize the congenital or early childhood-onset nonprogressive atrophy and weakness of the legs affecting both distal and proximal muscles, caused by altered motor neuron development or function.<sup><xref ref-type="bibr" rid="R3">3</xref></sup> The clinical presentation may overlap between spinal and distal motor neuron dysfunction. Correction of deformities is important, since these patients do not deteriorate in the later disease course. We identified 17 patients with clinical symptoms resembling SMA-LED, carrying mutations in <italic>SYT2</italic>, <italic>BICD2</italic>, and <italic>DYNC1H1</italic>, and no causative mutation was identified in 4 patients (<xref ref-type="fig" rid="F1">figure 1, I–J</xref>). No major common pathway can be highlighted by the pathomechanism of these genes, while different mutations in the same gene (such as <italic>DYNC1H1</italic>) may also cause different clinical presentations.</p><p>We reported that mutations in synaptic proteins can cause nonprogressive motor neuropathy and fatigable weakness with presynaptic neuromuscular junction (NMJ) defect (<italic>SYT2</italic>),<sup><xref ref-type="bibr" rid="R15">15</xref></sup> which can benefit from 3,4 diaminopyridine treatment.<sup><xref ref-type="bibr" rid="R33">33</xref></sup> Abnormal neuromuscular transmission has been shown in <italic>Drosophila</italic> and mouse models of <italic>GARS</italic> mutations.<sup><xref ref-type="bibr" rid="R34">34</xref>,<xref ref-type="bibr" rid="R35">35</xref></sup> Furthermore, a genetic defect of the presynaptic choline transport leads to HMN due to <italic>SLC5A7</italic> mutations.<sup><xref ref-type="bibr" rid="R36">36</xref></sup> Based on these findings, we studied neuromuscular transmission in 27 patients and substantial abnormalities (over and above that expected in the context of immature NMJs formed during denervation and reinnervation) were detected in 7 cases harboring different gene mutations. Further detailed studies of the NMJ are warranted, including genetically characterized patients. Neuromuscular transmission can be modified by several, already available compounds, which have been broadly used in congenital myasthenic syndromes, but not in hereditary neuropathies. We suggest performing repetitive stimulation and single fiber EMG as part of routine electrophysiologic studies in patients with HMN in order to uncover potentially treatable transmission defects.</p><p>We identified a subgroup of patients with inherited motor neuropathy, resembling multifocal demyelinating motor neuropathy or nodo-paranodopathy. Talipes and pure motor nerve involvement were caused by a novel mutation in <italic>ARHGEF10</italic>. Slow nerve conduction velocities have been implicated in <italic>ARHGEF10</italic> mutations and a 10-bp deletion in Leonberger dogs led to pelvic muscle weakness, stepping gait, and recurrent laryngeal nerve palsy.<sup><xref ref-type="bibr" rid="R37">37</xref></sup></p><p>A previously reported pathogenic mutation in <italic>TBX5</italic> was detected in a patient with demyelinating multifocal motor neuropathy. <italic>TBX5</italic> participates in transcriptional regulatory cascades and its pathogenic mutations, located within the DNA binding T-box domain, manifest in a rare condition called Holt-Oram syndrome with deformity of upper limbs, carpal tunnel syndrome, and cardiac anomalies.<sup><xref ref-type="bibr" rid="R27">27</xref></sup> We suggest that <italic>TBX5</italic> may cause demyelinating neuropathy affecting predominantly the motor nerves. No cardiac symptoms were detected in our patient. We detected a novel possibly causative <italic>STAT5B</italic> mutation in a sibling pair with motor neuropathy, ptosis, short stature, and dysmorphic facial features. Homozygous mutations in <italic>STAT5B</italic>, a signal transducer and activator of transcription, have been reported in only a handful of patients worldwide, all manifesting with postnatal growth retardation and occasional immunologic alterations.<sup><xref ref-type="bibr" rid="R38">38</xref></sup> Impaired <italic>STAT5B</italic> signaling may lead to aberrant peripheral myelination through cyclin D1 overexpression and may have an effect on neuronal growth and differentiation.<sup><xref ref-type="bibr" rid="R39">39</xref></sup> Finally, we detected a possibly causative de novo <italic>PTEN</italic> mutation in a patient with patchy motor neuropathy, focal demyelination, hamartoma-like skin lesions, and autism spectrum disorder. <italic>PTEN</italic>, a lipid phosphatase, inhibits phosphoinositide 3-kinase, which is also impaired in several forms of CMT (<italic>FIG4, FGD4, MTMR2, MTMR13/SBF2</italic>). It has been implicated in peripheral neural plasticity, axonal outgrowth, and hypermyelination. Experimental <italic>PTEN</italic> suppression in mice resulted in progressive peripheral neuropathy with tomacula formation and myelin outfoldings.<sup><xref ref-type="bibr" rid="R40">40</xref></sup></p><p>The identification of pathogenic mutations in the same genes in dHMN and motor CMT indicate that dHMN should not be classified as a different disease group. The detection of mutations in rare disease genes, not implicated in neuropathy to date, suggest that the neuropathy can be part of a more complex genetic disease and key clinical signs are important to recognize these diseases. These overlapping phenotypes highlight basic biological pathways in peripheral nerves that may be targeted to develop therapies for patients with inherited motor neuropathies.</p></sec>
<sec sec-type="supplementary-material">
<title>Supplementary Material</title>
<supplementary-material content-type="local-data" id="PMC_1">
<caption>
<title>Data Supplement</title>
</caption>
<media mime-subtype="html" mimetype="text" xlink:href="supp_88_13_1226__index.html"></media>
<media mime-subtype="pdf" mimetype="application" xlink:href="supp_WNL.0000000000003772_e-tables.pdf" xlink:role="associated-file"></media>
</supplementary-material>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="supplementary-material">
<p>Supplemental data at <ext-link ext-link-type="uri" xlink:href="http://neurology.org/lookup/doi/10.1212/WNL.0000000000003772">Neurology.org</ext-link></p>
</fn>
</fn-group>
<ack>
<title>ACKNOWLEDGMENT</title>
<p>The authors thank the members of the clinical team at the John Walton Muscular Dystrophy Research Centre (Newcastle), who may have seen some of the patients included in this cohort; the Northern Genetic Service and the UKGTN for providing diagnostic testing for some patients in this collective; and the Medical Research Council (MRC) Centre for Neuromuscular Diseases Biobank Newcastle and EuroBioBank for supporting this project.</p>
</ack>
<sec sec-type="contributions">
<title>AUTHOR CONTRIBUTIONS</title>
<p content-type="contributions">Boglarka Bansagi: drafting the manuscript, study concept and design, acquisition, analysis and interpretation of data. Helen Griffin: analysis and interpretation of data. Roger Whittaker: analysis and interpretation of data. Thalia Antoniadi: analysis and interpretation of data. Teresinha Evangelista: analysis and interpretation of data. James Miller: analysis and interpretation of data. Mark Greenslade: analysis and interpretation of data. Natalie Forester: analysis and interpretation of data. Jennifer Duff: analysis and interpretation of data. Anna Bradshaw: analysis and interpretation of data. Stephanie Kleinle: analysis and interpretation of data. Veronika Boczonadi: analysis and interpretation of data. Hannah Steele: analysis and interpretation of data. Venkatateswaran Ramesh: analysis and interpretation of data. Edit Franko: analysis and interpretation of data. Angela Pyle: analysis and interpretation of data. Hanns Lochmüller: analysis and interpretation of data, critical correction of the manuscript. Patrick F. Chinnery: analysis and interpretation of data, critical correction of the manuscript. Rita Horvath: study funding, drafting/revision of the manuscript, study concept and design, acquisition, analysis and interpretation of data.</p>
</sec>
<sec sec-type="funding">
<title>STUDY FUNDING</title>
<p content-type="funding">RH is a Wellcome Trust Investigator (109915/Z/15/Z), who receives support from the Medical Research Council (UK) (MR/N025431/1), the European Research Council (309548), the Wellcome Trust Pathfinder Scheme (201064/Z/16/Z), and the Newton Fund (UK/Turkey, MR/N027302/1). B.B. is a Medical Research Council (MRC)–funded Clinical Research Fellow and receives support from the MRC Centre for Neuromuscular Diseases. H.L. receives funding from the European Union Seventh Framework Programme (FP7/2007–2013) under grant agreement no. 305444 (RD-Connect) and 305121 (Neuromics). P.F.C. is a Wellcome Trust Senior Fellow in Clinical Science (101876/Z/13/Z) and a UK NIHR Senior Investigator, who receives support from the MRC Mitochondrial Biology Unit (MC_UP_1501/2), the Wellcome Trust Centre for Mitochondrial Research (096919Z/11/Z), the MRC (UK) Centre for Translational Muscle Disease (G0601943), EU FP7 TIRCON, and the NIH Research (NIHR) Biomedical Research Centre based at Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health.</p>
</sec>
<sec sec-type="disclosure">
<title>DISCLOSURE</title>
<p content-type="disclosure">The authors report no disclosures relevant to the manuscript. Go to <ext-link ext-link-type="uri" xlink:href="http://neurology.org/lookup/doi/10.1212/WNL.0000000000003772">Neurology.org</ext-link> for full disclosures.</p>
</sec>
<glossary>
<title>GLOSSARY</title>
<def-list>
<def-item>
<term id="G1">CI</term>
<def>
<p>confidence interval</p>
</def>
</def-item>
<def-item>
<term id="G2">CMT</term>
<def>
<p>Charcot-Marie-Tooth disease</p>
</def>
</def-item>
<def-item>
<term id="G3">dHMN</term>
<def>
<p>distal hereditary motor neuropathy</p>
</def>
</def-item>
<def-item>
<term id="G4">HMN</term>
<def>
<p>hereditary motor neuropathy</p>
</def>
</def-item>
<def-item>
<term id="G5">LED</term>
<def>
<p>lower extremity dominance</p>
</def>
</def-item>
<def-item>
<term id="G6">MAF</term>
<def>
<p>minor allele frequency</p>
</def>
</def-item>
<def-item>
<term id="G7">NCS</term>
<def>
<p>nerve conduction studies</p>
</def>
</def-item>
<def-item>
<term id="G8">NGS</term>
<def>
<p>next-generation sequencing</p>
</def>
</def-item>
<def-item>
<term id="G9">NMJ</term>
<def>
<p>neuromuscular junction</p>
</def>
</def-item>
<def-item>
<term id="G10">SMA</term>
<def>
<p>spinal muscular atrophy</p>
</def>
</def-item>
<def-item>
<term id="G11">SMARD1</term>
<def>
<p>spinal muscular atrophy with respiratory distress</p>
</def>
</def-item>
<def-item>
<term id="G12">WES</term>
<def>
<p>whole exome sequencing</p>
</def>
</def-item>
</def-list>
</glossary>
<ref-list>
<title>REFERENCES</title>
<ref id="R1">
<label>1.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rossor</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Kalmar</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Greensmith</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Reilly</surname><given-names>MM</given-names></name></person-group>
<article-title>The distal hereditary motor neuropathies</article-title>. <source/>J Neurol Neurosurg Psychiatry
<year>2012</year>;<volume>83</volume>:<fpage>6</fpage>–<lpage>14</lpage>.<pub-id pub-id-type="pmid">22028385</pub-id></mixed-citation>
</ref>
<ref id="R2">
<label>2.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Jonghe</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Timmerman</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Van Broeckhoven</surname><given-names>C</given-names></name>, <etal>et al</etal></person-group>
<article-title>2nd workshop of the European CMT consortium: 53rd ENMC international workshop on classification and diagnostic guidelines for Charcot-Marie-Tooth type 2 (CMT2-HMSN II) and distal hereditary motor neuropathy (distal HMN–spinal CMT), 26–28 September 1997, Naarden, the Netherlands</article-title>. <source/>Neuromuscul Disord
<year>1998</year>;<volume>8</volume>:<fpage>426</fpage>–<lpage>431</lpage>.<pub-id pub-id-type="pmid">9713862</pub-id></mixed-citation>
</ref>
<ref id="R3">
<label>3.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rossor</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Evans</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>Reilly</surname><given-names>MM</given-names></name></person-group>
<article-title>A practical approach to the genetic neuropathies</article-title>. <source/>Pract Neurol
<year>2015</year>;<volume>15</volume>:<fpage>187</fpage>–<lpage>198</lpage>.<pub-id pub-id-type="pmid">25898997</pub-id></mixed-citation>
</ref>
<ref id="R4">
<label>4.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Timmerman</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Strickland</surname><given-names>AV</given-names></name>, <name name-style="western"><surname>Züchner</surname><given-names>S</given-names></name></person-group>
<article-title>Genetics of Charcot-Marie-Tooth (CMT) disease within the frame of the human genome project success</article-title>. <source/>Genes<year>2014</year>;<volume>5</volume>:<fpage>13</fpage>–<lpage>32</lpage>.<pub-id pub-id-type="pmid">24705285</pub-id></mixed-citation>
</ref>
<ref id="R5">
<label>5.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Irobi</surname><given-names>J</given-names></name>, <name name-style="western"><surname>De Jonghe</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Timmerman</surname><given-names>V</given-names></name></person-group>
<article-title>Molecular genetics of distal hereditary motor neuropathies</article-title>. <source/>Hum Mol Gen
<year>2004</year>;<volume>13</volume>:<fpage>195</fpage>–<lpage>202</lpage>.</mixed-citation>
</ref>
<ref id="R6">
<label>6.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Irobi</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Dierick</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Jordanova</surname><given-names>A</given-names></name>, <etal>et al</etal></person-group>
<article-title>Unraveling the genetics of distal hereditary motor neuronopathies</article-title>. <source/>Neuromolecul Med
<year>2006</year>;<volume>8</volume>:<fpage>131</fpage>–<lpage>146</lpage>.</mixed-citation>
</ref>
<ref id="R7">
<label>7.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Luo</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Qian</surname><given-names>J</given-names></name>, <etal>et al</etal></person-group>
<article-title>FastUniq: a fast de novo duplicates removal tool for paired short reads</article-title>. <source/>PLoS One
<year>2012</year>;<volume>7</volume>:<fpage>e52249</fpage>.<pub-id pub-id-type="pmid">23284954</pub-id></mixed-citation>
</ref>
<ref id="R8">
<label>8.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Durbin</surname><given-names>R</given-names></name></person-group>
<article-title>Fast and accurate short read alignment with Burrows-Wheeler transform</article-title>. <source/>Bioinformatics
<year>2009</year>;<volume>25</volume>:<fpage>1754</fpage>–<lpage>1760</lpage>.<pub-id pub-id-type="pmid">19451168</pub-id></mixed-citation>
</ref>
<ref id="R9">
<label>9.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rehm</surname><given-names>HL</given-names></name>, <name name-style="western"><surname>Bale</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Bayrak-Toydemir</surname><given-names>P</given-names></name>, <etal>et al</etal></person-group>; <collab>Working Group of the American College of Medical Genetics and Genomics Laboratory Quality Assurance Committee</collab>. <article-title>ACMG clinical laboratory standards for next-generation sequencing</article-title>. <source/>Genet Med
<year>2013</year>;<volume>15</volume>:<fpage>733</fpage>–<lpage>747</lpage>.<pub-id pub-id-type="pmid">23887774</pub-id></mixed-citation>
</ref>
<ref id="R10">
<label>10.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pyle</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Smertenko</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Bargiela</surname><given-names>D</given-names></name>, <etal>et al</etal></person-group>
<article-title>Exome sequencing in undiagnosed inherited and sporadic ataxias</article-title>. <source/>Brain
<year>2015</year>;<volume>138</volume>:<fpage>276</fpage>–<lpage>283</lpage>.<pub-id pub-id-type="pmid">25497598</pub-id></mixed-citation>
</ref>
<ref id="R11">
<label>11.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Casasnovas</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Banchs</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Cassereau</surname><given-names>J</given-names></name>, <etal>et al</etal></person-group>
<article-title>Phenotypic spectrum of <italic>MFN2</italic> mutations in the Spanish population</article-title>. <source/>J Med Genet
<year>2010</year>;<volume>47</volume>:<fpage>249</fpage>–<lpage>256</lpage>.<pub-id pub-id-type="pmid">19889647</pub-id></mixed-citation>
</ref>
<ref id="R12">
<label>12.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nightingale</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Pfeffer</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Horvath</surname><given-names>R</given-names></name></person-group>
<article-title>Chronic and slowly progressive weakness of the legs and hands</article-title>. <source/>BMJ
<year>2014</year>;<volume>348</volume>:<fpage>g459</fpage>.<pub-id pub-id-type="pmid">24473995</pub-id></mixed-citation>
</ref>
<ref id="R13">
<label>13.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cottenie</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Kochanski</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Jordanova</surname><given-names>A</given-names></name>, <etal>et al</etal></person-group>
<article-title>Truncating and missense mutations in <italic>IGHMBP2</italic> cause Charcot-Marie Tooth disease type 2</article-title>. <source/>Am J Hum Genet
<year>2014</year>;<volume>95</volume>:<fpage>590</fpage>–<lpage>601</lpage>.<pub-id pub-id-type="pmid">25439726</pub-id></mixed-citation>
</ref>
<ref id="R14">
<label>14.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Herrmann</surname><given-names>DN</given-names></name>, <name name-style="western"><surname>Horvath</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Sowden</surname><given-names>JE</given-names></name>, <etal>et al</etal></person-group>
<article-title>Synaptotagmin 2 mutations cause an autosomal-dominant form of Lambert-Eaton myasthenic syndrome and nonprogressive motor neuropathy</article-title>. <source/>Am J Hum Genet
<year>2014</year>;<volume>95</volume>:<fpage>332</fpage>–<lpage>339</lpage>.<pub-id pub-id-type="pmid">25192047</pub-id></mixed-citation>
</ref>
<ref id="R15">
<label>15.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bansagi</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Griffin</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Ramesh</surname><given-names>V</given-names></name>, <etal>et al</etal></person-group>
<article-title>The p.Ser107Leu in <italic>BICD2</italic> is a mutation “hot spot” causing distal spinal muscular atrophy</article-title>. <source/>Brain
<year>2015</year>;<volume>138</volume>:<fpage>e391</fpage>.<pub-id pub-id-type="pmid">26063656</pub-id></mixed-citation>
</ref>
<ref id="R16">
<label>16.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Evangelista</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Bansagi</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Pyle</surname><given-names>A</given-names></name>, <etal>et al</etal></person-group>
<article-title>Phenotypic variability of TRPV4-related neuropathies</article-title>. <source/>Neuromuscul Disord
<year>2015</year>;<volume>25</volume>:<fpage>516</fpage>–<lpage>521</lpage>.<pub-id pub-id-type="pmid">25900305</pub-id></mixed-citation>
</ref>
<ref id="R17">
<label>17.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bansagi</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Antoniadi</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Burton-Jones</surname><given-names>S</given-names></name>, <etal>et al</etal></person-group>
<article-title>Genotype/phenotype correlations in AARS-related neuropathy in a cohort of patients from the United Kingdom and Ireland</article-title>. <source/>J Neurol
<year>2015</year>;<volume>262</volume>:<fpage>1899</fpage>–<lpage>1908</lpage>.<pub-id pub-id-type="pmid">26032230</pub-id></mixed-citation>
</ref>
<ref id="R18">
<label>18.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haberlova</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Mazanec</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Ridzon</surname><given-names>P</given-names></name>, <etal>et al</etal></person-group>
<article-title>Phenotypic variability in a large Czech family with a dynamin 2-associated Charcot-Marie-Tooth neuropathy</article-title>. <source/>J Neurogenet
<year>2011</year>;<volume>25</volume>:<fpage>182</fpage>–<lpage>188</lpage>.<pub-id pub-id-type="pmid">22091729</pub-id></mixed-citation>
</ref>
<ref id="R19">
<label>19.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Albulym</surname><given-names>OM</given-names></name>, <name name-style="western"><surname>Kennerson</surname><given-names>ML</given-names></name>, <name name-style="western"><surname>Harms</surname><given-names>MB</given-names></name>, <etal>et al</etal></person-group>
<article-title><italic>MORC2</italic> mutations cause axonal Charcot-Marie-Tooth disease with pyramidal signs</article-title>. <source/>Ann Neurol
<year>2016</year>;<volume>79</volume>:<fpage>419</fpage>–<lpage>427</lpage>.<pub-id pub-id-type="pmid">26659848</pub-id></mixed-citation>
</ref>
<ref id="R20">
<label>20.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bansagi</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Lewis-Smith</surname><given-names>DJ</given-names></name>, <name name-style="western"><surname>Pal</surname><given-names>E</given-names></name>, <etal>et al</etal></person-group>
<article-title>Phenotypic convergence of Menkes and Wilson's disease</article-title>. <source/>Neurol Genet
<year>2016</year>;<volume>2</volume>:<fpage>e119</fpage>.<pub-id pub-id-type="pmid">27878136</pub-id></mixed-citation>
</ref>
<ref id="R21">
<label>21.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Foley</surname><given-names>AR</given-names></name>, <name name-style="western"><surname>Menezes</surname><given-names>MP</given-names></name>, <name name-style="western"><surname>Pandraud</surname><given-names>A</given-names></name>, <etal>et al</etal></person-group>
<article-title>Treatable childhood neuronopathy caused by mutations in riboflavin transporter <italic>RFVT2</italic></article-title>. <source/>Brain
<year>2014</year>;<volume>137</volume>:<fpage>44</fpage>–<lpage>56</lpage>.<pub-id pub-id-type="pmid">24253200</pub-id></mixed-citation>
</ref>
<ref id="R22">
<label>22.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pyle</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Ramesh</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Bartsakoulia</surname><given-names>M</given-names></name>, <etal>et al</etal></person-group>
<article-title>Behr's syndrome is typically associated with disturbed mitochondrial translation and mutations in the <italic>C12orf65</italic> gene</article-title>. <source/>J Neuromuscul Dis
<year>2014</year>;<volume>1</volume>:<fpage>55</fpage>–<lpage>63</lpage>.</mixed-citation>
</ref>
<ref id="R23">
<label>23.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Daud</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Griffin</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Douroudis</surname><given-names>K</given-names></name>, <etal>et al</etal></person-group>
<article-title>Whole exome sequencing and the clinician: we need clinical skills and functional validation in variant filtering</article-title>. <source/>J Neurol
<year>2015</year>;<volume>262</volume>:<fpage>1673</fpage>–<lpage>1677</lpage>.<pub-id pub-id-type="pmid">25957632</pub-id></mixed-citation>
</ref>
<ref id="R24">
<label>24.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu-Wai-Man</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Pyle</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Griffin</surname><given-names>H</given-names></name>, <etal>et al</etal></person-group>
<article-title>Abnormal retinal thickening is a common feature among patients with ARSACS-related phenotypes</article-title>. <source/>Br J Ophthalmol
<year>2014</year>;<volume>98</volume>:<fpage>711</fpage>–<lpage>713</lpage>.<pub-id pub-id-type="pmid">24457356</pub-id></mixed-citation>
</ref>
<ref id="R25">
<label>25.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DiVincenzo</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Elzinga</surname><given-names>CD</given-names></name>, <name name-style="western"><surname>Medeiros</surname><given-names>AC</given-names></name>, <etal>et al</etal></person-group>
<article-title>The allelic spectrum of Charcot-Marie-Tooth disease in over 17,000 individuals with neuropathy</article-title>. <source/>Mol Genet Genomic Med
<year>2014</year>;<volume>2</volume>:<fpage>522</fpage>–<lpage>529</lpage>.<pub-id pub-id-type="pmid">25614874</pub-id></mixed-citation>
</ref>
<ref id="R26">
<label>26.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chow</surname><given-names>CY</given-names></name>, <name name-style="western"><surname>Landers</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Bergren</surname><given-names>SK</given-names></name>, <etal>et al</etal></person-group>
<article-title>Deleterious variants of FIG4, a phosphoinositide phosphatase, in patients with ALS</article-title>. <source/>Am J Hum Genet
<year>2009</year>;<volume>84</volume>:<fpage>85</fpage>–<lpage>88</lpage>.<pub-id pub-id-type="pmid">19118816</pub-id></mixed-citation>
</ref>
<ref id="R27">
<label>27.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heinritz</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Shou</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Moschik</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Froster</surname><given-names>UG</given-names></name></person-group>
<article-title>The human <italic>TBX5</italic> gene mutation database</article-title>. <source/>Hum Mutat
<year>2005</year>;<volume>26</volume>:<fpage>397</fpage>.</mixed-citation>
</ref>
<ref id="R28">
<label>28.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Foley</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Schofield</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Eglon</surname><given-names>G</given-names></name>, <etal>et al</etal></person-group>
<article-title>Charcot-Marie-Tooth disease in Northern England</article-title>. <source/>J Neurol Neurosurg Psychiatry
<year>2012</year>;<volume>83</volume>:<fpage>572</fpage>–<lpage>573</lpage>.<pub-id pub-id-type="pmid">21984771</pub-id></mixed-citation>
</ref>
<ref id="R29">
<label>29.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Norwood</surname><given-names>FL</given-names></name>, <name name-style="western"><surname>Harling</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Chinnery</surname><given-names>PF</given-names></name>, <etal>et al</etal></person-group>
<article-title>Prevalence of genetic muscle disease in Northern England: in-depth analysis of a muscle clinic population</article-title>. <source/>Brain
<year>2009</year>;<volume>132</volume>:<fpage>3175</fpage>–<lpage>3186</lpage>.<pub-id pub-id-type="pmid">19767415</pub-id></mixed-citation>
</ref>
<ref id="R30">
<label>30.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pearn</surname><given-names>J</given-names></name></person-group>
<article-title>Incidence, prevalence, and gene frequency studies of chronic childhood spinal muscular atrophy</article-title>. <source/>J Med Genet
<year>1978</year>;<volume>15</volume>:<fpage>409</fpage>–<lpage>413</lpage>.<pub-id pub-id-type="pmid">745211</pub-id></mixed-citation>
</ref>
<ref id="R31">
<label>31.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dierick</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Baets</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Irobi</surname><given-names>J</given-names></name>, <etal>et al</etal></person-group>
<article-title>Relative contribution of mutations in genes for autosomal dominant distal hereditary motor neuropathies: a genotype-phenotype correlation study</article-title>. <source/>Brain
<year>2008</year>;<volume>131</volume>:<fpage>1217</fpage>–<lpage>1227</lpage>.<pub-id pub-id-type="pmid">18325928</pub-id></mixed-citation>
</ref>
<ref id="R32">
<label>32.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Den Bosch</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Timmerman</surname><given-names>V</given-names></name></person-group>
<article-title>Genetics of motor neuron disease</article-title>. <source/>Curr Neurol Neurosci Rep
<year>2006</year>;<volume>6</volume>:<fpage>423</fpage>–<lpage>431</lpage>.<pub-id pub-id-type="pmid">16928353</pub-id></mixed-citation>
</ref>
<ref id="R33">
<label>33.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Whittaker</surname><given-names>RG</given-names></name>, <name name-style="western"><surname>Herrmann</surname><given-names>DN</given-names></name>, <name name-style="western"><surname>Bansagi</surname><given-names>B</given-names></name>, <etal>et al</etal></person-group>
<article-title>Electrophysiologic features of <italic>SYT2</italic> mutations causing a treatable neuromuscular syndrome</article-title>. <source/>Neurology
<year>2015</year>;<volume>85</volume>:<fpage>1964</fpage>–<lpage>1971</lpage>.<pub-id pub-id-type="pmid">26519543</pub-id></mixed-citation>
</ref>
<ref id="R34">
<label>34.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ermanoska</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Motley</surname><given-names>WW</given-names></name>, <name name-style="western"><surname>Leitão-Gonçalves</surname><given-names>R</given-names></name>, <etal>et al</etal></person-group>
<article-title>CMT-associated mutations in glycyl- and tyrosyl-tRNA synthetases exhibit similar pattern of toxicity and share common genetic modifiers in Drosophila</article-title>. <source/>Neurobiol Dis
<year>2014</year>;<volume>68</volume>:<fpage>180</fpage>–<lpage>189</lpage>.<pub-id pub-id-type="pmid">24807208</pub-id></mixed-citation>
</ref>
<ref id="R35">
<label>35.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sleigh</surname><given-names>JN</given-names></name>, <name name-style="western"><surname>Grice</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Burgess</surname><given-names>RW</given-names></name>, <etal>et al</etal></person-group>
<article-title>Neuromuscular junction maturation defects precede impaired lower motor neuron connectivity in Charcot-Marie-Tooth type 2D mice</article-title>. <source/>Hum Mol Genet
<year>2014</year>;<volume>23</volume>:<fpage>2639</fpage>–<lpage>2650</lpage>.<pub-id pub-id-type="pmid">24368416</pub-id></mixed-citation>
</ref>
<ref id="R36">
<label>36.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barwick</surname><given-names>KE</given-names></name>, <name name-style="western"><surname>Wright</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Al-Turki</surname><given-names>S</given-names></name>, <etal>et al</etal></person-group>
<article-title>Defective presynaptic choline transport underlies hereditary motor neuropathy</article-title>. <source/>Am J Hum Genet
<year>2012</year>;<volume>91</volume>:<fpage>1103</fpage>–<lpage>1107</lpage>.<pub-id pub-id-type="pmid">23141292</pub-id></mixed-citation>
</ref>
<ref id="R37">
<label>37.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ekenstedt</surname><given-names>KJ</given-names></name>, <name name-style="western"><surname>Becker</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Minor</surname><given-names>KM</given-names></name>, <etal>et al</etal></person-group>
<article-title>An ARHGEF10 deletion is highly associated with a juvenile-onset inherited polyneuropathy in Leonberger and Saint Bernard dogs</article-title>. <source/>PLoS Genet
<year>2014</year>;<volume>10</volume>:<fpage>e1004635</fpage>.<pub-id pub-id-type="pmid">25275565</pub-id></mixed-citation>
</ref>
<ref id="R38">
<label>38.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pugliese-Pires</surname><given-names>PN</given-names></name>, <name name-style="western"><surname>Tonelli</surname><given-names>CA</given-names></name>, <name name-style="western"><surname>Dora</surname><given-names>JM</given-names></name>, <etal>et al</etal></person-group>
<article-title>A novel STAT5B mutation causing GH insensitivity syndrome associated with hyperprolactinemia and immune dysfunction in two male siblings</article-title>. <source/>Eur J Endocrinol
<year>2010</year>;<volume>163</volume>:<fpage>349</fpage>–<lpage>355</lpage>.<pub-id pub-id-type="pmid">20538865</pub-id></mixed-citation>
</ref>
<ref id="R39">
<label>39.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kalita</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Gupta</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Singh</surname><given-names>P</given-names></name>, <etal>et al</etal></person-group>
<article-title>IGF-1 stimulated upregulation of cyclin D1 is mediated via STAT5 signaling pathway in neuronal cells</article-title>. <source/>IUBMB Life
<year>2013</year>;<volume>65</volume>:<fpage>462</fpage>–<lpage>471</lpage>.<pub-id pub-id-type="pmid">23504816</pub-id></mixed-citation>
</ref>
<ref id="R40">
<label>40.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goebbels</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Oltrogge</surname><given-names>JH</given-names></name>, <name name-style="western"><surname>Wolfer</surname><given-names>S</given-names></name>, <etal>et al</etal></person-group>
<article-title>Genetic disruption of Pten in a novel mouse model of tomaculous neuropathy</article-title>. <source/>EMBO Mol Med
<year>2012</year>;<volume>4</volume>:<fpage>486</fpage>–<lpage>499</lpage>.<pub-id pub-id-type="pmid">22488882</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>